At Microbionwe Are Developing A New Class Of Therapeutic Drugs To Tackle The Unmet Needs Of Rarechronicand Serious Diseasesour Lead Drug Candidatepravibismaneis A First In Class Therapeutic With A Novel Triad Of Activitiesanti Infectiveantibiofilmand Anti Inflammatorythese Synergistic Properties Uniquely Position Pravibismane To Address Conditions Where Conventional Treatments Often Fail We Are Advancing Multiple Pravibismane Formulations Through Clinical Developmentfocusing On Indications With Significant Unmet Needs Topical Pravibismane For Diabetic Foot Ulcers Infectionsphase 3 Studies Planned For 2025 Local Surgical Pravibismane For Orthopedic Infectionsphase 2A Studies Completedinhaled Pravibismane For Pulmonary Diseases Including Nontuberculous Mycobacteria Lung Infectionsready For First In Human Phase 1 Studies Pravibismane Has Been Granted Fda Qualified Infectious Disease Productqidp Fast Trackand Orphan Drug Designationsunderscoring Its Disruptive Potentialto Datepravibismane Development Has Been Supported By Over $22M In Grants Awarded From Leading Organizationsincluding The U Sdepartment Of Defensenihcarb Xand The Cystic Fibrosis Foundation We Are Actively Seeking Strategic Licensing And Development Partners To Advance Phase 3 Trialsexplore New Indicationse G Immunomodulation And Inflammation And Bring Pravibismane To Patients Worldwide
